|
Clinical Trial of Acid Reflux Therapy in Asthma Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Clinical Trial of Acid Reflux Therapy in Asthma conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Clinical Trial of Acid Reflux Therapy in Asthma Clinical research trials and Clinical Trial of Acid Reflux Therapy in Asthma healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Clinical Trial of Acid Reflux Therapy in Asthma. Clinical Trial of Acid Reflux Therapy in Asthma Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Clinical Trial of Acid Reflux Therapy in Asthma clinical trial. Test subjects typically receive the most effective healthcare possible for their Clinical Trial of Acid Reflux Therapy in Asthma condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clinical Trial of Acid Reflux Therapy in Asthma  Clinical Trial of Acid Reflux Therapy in Asthma
Clinical Trial of Acid Reflux Therapy in Asthma
For Condition: Lung Diseases,Asthma,Lung Diseases, Obstructive
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
Details: BACKGROUND: Gastroesophageal reflux (GERD) is frequent in asthmatics with poor asthma control, often occurs without symptoms, and can induce bronchoconstriction. Poorly controlled asthmatics are often treated for GERD with drugs that suppress gastric acid, but this treatment is expensive and the benefit of such treatment is not established. Proton pump inhibitors are a relatively new class of medications that provide highly effective treatment for GERD and associated problems. This success has led many doctors to begin PPI treatment in their asthma patients in an attempt to achieve better asthma control. DESIGN NARRATIVE: The randomized, placebo-controlled trial will enroll 400 asthmatics, ages 18-60, who have poor asthma control on inhaled steroids, defined on the basis of excessive bronchodilator use, nocturnal awakenings, or frequent exacerbations. Participants will be randomly assigned to treatment with either a proton pump inhibitor, esomeprazole (Nexium) 40 mg twice a day, or matching placebo. The presence, severity, and temporal relationship of GERD to asthma symptoms will be documented with 24 hour ambulatory esophageal pH probe monitoring, but participants will be enrolled irrespective of the severity of GERD. The primary outcome measure is the proportion of participants who have exacerbations of asthma within a 6-month period defined by asthma diaries and interviews. Secondary outcome measures include asthma symptom and control scores, asthma-specific and generic health-related quality of life, GERD symptoms, health care use, pulmonary function, and airways reactivity. Pre-specified subgroup analyses will be conducted to determine if there are clinical or demographic characteristics that predict benefit from treatment of GERD in asthma.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Placebo Control
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: Both
Protocol Entry Criteria: An estimated 400 asthmatics, ages 18-60, who have poor asthma control on inhaled steroids, defined on the basis of excessive bronchodilator use, nocturnal awakenings, or frequent exacerbations.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertWise, , Johns Hopkins University School of Public Health
Additional Information:
Study ID Numbers: 157;
Study Start Date: September 2003
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00069823
Other Asthma Studies:
1. Epidemiology of Sleep Disordered Breathing in Children
2. Premature Birth and its Sequelae in Women
3. Intervention for Hispanic Children with Asthma
4. NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy
5. Assessment of Lung Inflammation in Patients with Atopic Asthma Using Positron Emission Tomography
Related Studies:
Other Asthma Clinical Trials
Other Clinical Trials
Other Clinical Trials
Clinical Trial of Acid Reflux Therapy in Asthma
|
|
|
|
|
|
|
|
